検索結果一覧

一般口演 / Oral Session

一般口演 12 (Oral Session 12) :悪性リンパ腫:多施設共同研究
 
日程
2013年10月11日(金)
時間
10:30 - 11:30
会場
第8会場 / Room No.8 (ロイトン札幌 2F ハイネス)
座長・司会
藤田 浩之 (Hiroyuki Fujita):1
1:済生会横浜市南部病院 血液内科

前へ戻る


Bendamustine and Rituximab for Relapsed/Refractory Indolent B-Lymphoma -Final Results- BRB Study

演題番号 : OS-1-56

松本 公宏 (Kimihiro Matsumoto):1,2,9、高山 信之 (Nobuyuki Takayama):2,3、相佐 好伸 (Yoshinobu Aisa):2,4、上野 博則 (Hironori Ueno):2,5、萩原 政夫 (Masao Hagiwara):2,6、渡辺 健太郎 (Kentaro Watanabe):2,7、山田 悠史 (Yuji Yamada):2,8、中谷 綾 (Aya Nakaya):2、陳 建綱 (C.K. Chen):2,11、増田 義洋 (Yoshihiro Masuda):2,12、石田 明 (Akari Ishida):2,13、内田 秀夫 (Hideo Uchida):2,10、清水 隆之 (Takayuki Shimizu):2,9、塚田 唯子 (Yuiko Tsukada):2,7、仲里 朝周 (Tomonori Nakazato):2,4、佐藤 範英 (Norihide Sato):2,3、菊池 隆秀 (Takahide Kikuchi):2,7、横山 明弘 (Akihiro Yokoyama):2,5、朴 載源 (Saigen Boku):2,5、岡野 裕 (Yutaka Okano):2,8、菊池 拓 (Taku Kikuchi):2,9、松木 絵里 (Eri Matsuki):2,9、石澤 丈 (Jo Ishizawa):2,9、上田 智基 (Tomoki Ueda):2,9、森 毅彦 (Takehiko Mori):2,9、宮川 義隆 (Yoshitaka Miyakawa):2,8,9、横山 健次 (Kenji Yokoyama):2,9、中島 秀明 (Hideaki Nakajima):2,9、矢野 尊啓 (Takahiro Yano):2,5、岡本 真一郎 (Shinichiro Okamoto):1,2,9

1:Div. Hematol, Dept. Int. Med., Tokyo Dental Univ. Hosp.、2:Keio BRB Study Group、3:2nd Dept. Int. Med. Kyorin Univ.、4:Dept. of Hematology, Yokohama Municipal Citizen's Hospital、5:Dept. of Hematology, Nat. Hosp. Org. Tokyo Med. Center、6:Dept. of Hematology, Eiju General Hospital、7:Dept. of Hematology, Tokyo Saiseikai Central Hospital、8:Kawasaki Municipal Hosp.、9:Div. Hematol., Dept. Int. Med., Keio Univ.、10:Dept. of Internal Medicine, Tokyo Electric Power Company Hospital、11:Dept. of Internal Medicine, Keiyu Hospital、12:Div. of Haematol, Saiseikai Utsunomiya Hosp.、13:Tachikawa Hosp.

Bendamustine and Rituximab for Relapsed/Refractory Indolent B-Lymphoma -Final Results- BRB Study

Phase 1/2 study of brentuximab vedotin in Japanese patients with relapsed/refractory HL or sALCL

演題番号 : OS-1-57

丸山 大 (Dai Maruyama):1、小椋 美知則 (Michinori Ogura):2、飛内 賢正 (Kensei Tobinai):1、畠 清彦 (Kiyohiko Hatake):3、石澤 賢一 (Kenichi Ishizawa):4、鵜池 直邦 (Naokuni Uike):5、内田 俊樹 (Toshiki Uchida):2、鈴木 達也 (Tatsuya Suzuki):2、青木 智広 (Tomohiro Aoki):2、渡辺 隆 (Takashi Watanabe):1、横山 雅大 (Masahiro Yokoyama):3、田窪 孝年 (Takatoshi Takubo):6、影原 英明 (Hideaki Kagehara):6、松島 孝文 (Takafumi Matsushima):6

1:Department of Hematology, National Cancer Center Hospital, Tokyo, Japan、2:Department of Hematology and Oncology, Nagoya Daini Red Cross Hospital, Nagoya, Japan、3:Department of Hematology and Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan、4:Department of Hematology and Rheumatology, Tohoku University Hospital, Sendai, Japan、5:Department of Hematology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan、6:Takeda Bio Development Center Limited, Tokyo, Japan

Phase 1/2 study of brentuximab vedotin in Japanese patients with relapsed/refractory HL or sALCL

Phase I study of R-CVP plus inotuzumab ozogamicin in CD22+ B-cell non-Hodgkin lymphoma (B-NHL)

演題番号 : OS-1-58

Michinori Ogura:1、畠 清彦 (Kiyohiko Hatake):2、Andrew Davies:3、Michael Crump:4、Kensei Tobinai:5、Mitchell R Smith:6、Fritz Offner:7、Revathi Ananthakrishnan:8、Taro Ishibashi:9、Luisa Paccagnella:8、Erik Vandendries:8、David A MacDonald:10

1:Department of Hematology & Oncology, Nagoya Daini Red Cross Hospital, Japan、2:Cancer Institute Hospital, Tokyo, Japan、3:Cancer Sciences Division, Somers Cancer Research Building, University of Southampton, Southampton, United Kingdom、4:Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada、5:National Cancer Center Hospital, Tokyo, Japan、6:Fox Chase Cancer Center, Philadelphia, PA, USA (Current affiliation is Cleveland Clinic, Cleveland, OH, USA)、7:Ghent University Hospital, Ghent, Belgium、8:Pfizer, Cambridge, MA and Groton, CT, USA、9:Pfizer Japan, Tokyo, Japan、10:Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada

Phase I study of R-CVP plus inotuzumab ozogamicin in CD22+ B-cell non-Hodgkin lymphoma (B-NHL)

Phase I study of inotuzumab ozogamicin with R-GDP for relapsed CD22+ B-cell non-Hodgkin lymphoma

演題番号 : OS-1-59

Michinori Ogura:1、Yeow-Tee Goh:2、Andrew Davies:3、Nam H Dang:4、Luisa Paccagnella:5、Revathi Ananthakrishnan:5、Erik Vandendries:5、Randeep Sangha:6

1:Department of Hematology & Oncology, Nagoya Daini Red Cross Hospital, Japan、2:Singapore General Hospital, Singapore、3:Cancer Sciences Division, Somers Cancer Research Building, University of Southampton, Southampton, United Kingdom、4:University of Florida, Gainesville, FL, US、5:Pfizer, Cambridge, MA and Groton, CT, USA、6:Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada

Phase I study of inotuzumab ozogamicin with R-GDP for relapsed CD22+ B-cell non-Hodgkin lymphoma

A multicenter, double-blind, randomized Phase III study comparing KRN125 with filgrastim in lymphoma

演題番号 : OS-1-60

宮崎 泰彦 (Yasuhiko Miyazaki):1、久保 恒明 (Koumei Kubo):2、村山 徹 (Tohru Murayama):3、薄井 紀子 (Noriko Usui):4、浦部 晶夫 (Akio Urabe):5、田村 和夫 (Kazuo Tamura):6、堀田 知光 (Tomomitsu Hotta):7

1:Department of Hematology, Oita Prefectural Hospital, Oita, Japan、2:Department of Hematology, Aomori Prefectural Central Hospital, Aomori, Japan、3:Department of Hematology, Hyogo Cancer Center, Hyogo, Japan、4:Division of Hematology and Oncology, Jikei University School of Medicine, Tokyo, Japan、5:Center for Preventive Medicine, NTT Kanto Medical Center, Tokyo, Japan、6:Division of Medical Oncology, Hematology, and Infectious Disease, Fukuoka University, Fukuoka, Japan、7:National Cancer Center, Tokyo, Japan

A multicenter, double-blind, randomized Phase III study comparing KRN125 with filgrastim in lymphoma